Novartis Fraudulent Marketing Deception
Novartis sales reps knew Tasigna was linked to atherosclerosis
Tuesday, May 29, 2018 - Medical patients have the right to all of the facts pertaining to the side effects of their medicine so that they can make an informed decision as to the treatment of their disease. When material facts are withheld or misstated unforeseen side effects can have life and death consequences. Medicines used in the treatment of cancer are so toxic that they can easily cause death all by themselves if misused and can only be distributed by "specialty pharmacies," unlike other drugs like antibiotics that are more readily available at popular commercial drug stores. Consumers expect more from a specialty pharmacist and their integrity must be beyond reproach. This bond of trust was breached when Novartis maker of the anti-cancer chemotherapy drug, Tasigna, broke the law with a fraudulent and illegal marketing scheme to incentivize specialty pharmacists to prescribe the deadly drug to unsuspecting and trusting cancer patients.
Several years ago, Gleevec, the original and top-selling anti-cancer drug marketed by Novartis, was heralded as a breakthrough in fighting cancer. Studies showed that patients taking Gleevec had what is called a "complete hematological response." In oncology terms, this means that a cancer patient's white blood cell count returned to within a normal range in 53 out of 54 patients studied within four weeks of the start of treatment. After 5 years, over 98 percent had normal levels of white blood cells. Because of Gleevec, survival rates skyrocketed as did Gleevec sales. Novartis booked close to $5 billion in sales in 2015 from the Gleevec brand alone. Problems started, however, when the drug's limited patent was set to expire at the end of the year, and cheaper generic knock-offs were poised to devastate Novartis' share of the anti-cancer drug market. Years earlier, Novartis had lost billions in sales when another of their drugs, Diovan, went off patent and sales were cannibalized by generic drug makers. Novartis was not going to let that happen again.
To make up for what was sure to be the loss of billions of dollars in revenue from Gleevec sales, Novartis brought Tasigna, a more potent anti-cancer drug to market prior to Gleevec's patent expiration. In what the US Department of Justice termed, "fraudulent, misleading and illegal marketing tactics," Novartis sales representatives incentivized specialty pharmacists to refill existing Gleevec prescriptions with Tasigna without approval from oncologists or patients. Novartis reps conducted illegal sales campaigns and paid cash bonuses to pharmacists that sold the most Tasigna each month. A Novartis sales manager turned company whistleblower testified that Novartis did all of this whilst knowing that Tasigna had the devastating side effect of causing necrosis of the feet, paralysis from massive strokes, and sudden death from heart attacks. For their deception, Novartis was sued by the DOJ and fined $1 billion dollars settling for a payment of $390 million. According to a DOJ spokesperson, "Novartis incentivized and pressured the pharmacies to emphasize benefits to patients while understating the drug's serious, potentially life-threatening side effects." Armed with this ironclad evidence against the company, Tasigna patients are hiring Tasigna atherosclerosis lawyers and filing claims against Novartis for failing to warn them of Tasigna's deadly side effect.
More Recent Tasigna Atherosclerosis Lawsuit News:
- Tasigna Patients Are Warned of The Risk of Sudden Death | 5/13/2019
- Tasigna's Atherosclerosis Risk Is Well-Documented By Researchers For Peer-Reviewed Medical Publications | 5/8/2019
- Tasigna's Atherosclerosis Side Effect Is Not Forgotten | 4/17/2019
- Trying Tasigna As A Last Resort May Make Sense To Terminally Ill Cancer Patients | 4/12/2019
- Novartis Claim Tasigna Can Help Parkinson's Patients is Met With Skepticism | 4/4/2019
- Novartis Failed To Warn American Doctors Who In Turn Failed To Warn Patients of Tasigna's Atherosclerosis Risks | 3/20/2019
- Tasigna Is Being Repurposed To Treat Parkinson's Disease | 3/14/2019
- Some Patient Can Cease Taking Tasigna But They May Have Already Developed Atherosclerosis | 3/12/2019
- Health Experts Warn of Potentially Deadly Tasigna Drug Interactions | 3/5/2019
- The Potential To Someday Stop Tasigna Treatments Should Not Be An Incentive To Take The Drug | 2/28/2019
- Tasigna Studies Show The Drug Should Be Taken As A Last Resort | 2/24/2019
- Cancer Doctors and Medical Websites Should Take Tasigna's Atherosclerosis Risks More Seriously | 2/18/2019
- The FDA May Be Putting Children's Lives In Danger By Ignoring Tasigna's Atherosclerosis Risk | 2/12/2019
- The FDA May Have Overlooked Tasigna's Atherosclerosis Side Effect When Approving its Usage by Children | 2/5/2019
- Children With Cancer May Now Start Taking Tasigna | 1/31/2019
- Studies Reported by Leading Experts Focus on Tasigna Toxicity | 1/25/2019
- Novartis Has a History of Deceptive Sale Practices That Taints Their Credibility | 1/22/2019
- Novartis Changes Tasigna's Label But Not Its Toxicity | 1/16/2019
- Tasigna Doctors May Be Ignoring Atherosclerosis Risks | 1/11/2019
- Cancer Doctors Prescribing Tasigna Should Be Trained Like Heart Specialists | 1/8/2019
- Tasigna is Effective in Treating Chronic Myeloid Leukemia | 1/1/2019
- Early Warning Signs of Chronic Myeloid Leukemia (CML) | 12/5/2018
- CML Patients in Remission May Discontinue Taking Tasigna | 12/1/2018
- Tasigna's Atherosclerosis Warnings is Rarely Seen by Cancer Patients | 11/28/2018
- Novartis' Failure to Warn the FDA May Have Led to Atherosclerosis in As Many As One in Four Tasigna Patients | 11/12/2018
- Novartis Highlights Tasigna's Effectiveness yet Downplays The Drug's Deadly Side Effects | 11/8/2018
- Novartis Takes Advantage of Tasigna's Catch 22 | 10/30/2018
- Tasigna Atherosclerosis Ignored by Novartis Celebrity Spokesperson | 10/24/2018
- Oncologists May Be Ignoring the Cardiovascular Side Effects of Tasigna | 10/16/2018
- The FDA Atherosclerosis Warning Came Too Late for Tasigna Patients in the United States | 10/8/2018
- One-Third of Tasigna Patients Could Face Coronary Bypass Surgery | 10/4/2018
- Billion Dollar Fines Are Just a Cost of Doing Business For Novartis | 10/2/2018
- Cancer Patients Should View Novartis' New Tasigna Label With Scepticism | 9/28/2018
- Novartis Boasts of Tasigna's Effectiveness While Ignoring the Atherosclerosis Side Effects | 9/27/2018
- Tasigna May Be One Of The Most Deadly Drugs On The Market Today | 9/25/2018
- NBA Star's Arterial Blockage May Have Been Caused by Taking Tasigna | 9/22/2018
- Taxpayers Saved Billions By Novartis AG Whistleblower | 9/20/2018
- Tasigna Carries The Unacceptable Risk of Developing Atherosclerosis and Amputation | 9/19/2018
- Tasigna's Cancer-Fighting Success May Be Tempered By The Risk Of Sudden Death | 9/17/2018
- Novartis Pulled No Punches In Warning Canadians About The Atherosclerosis Related Side effects Of Tasigna Yet Said Nothing To Warn Cancer Patients In The United States. | 9/11/2018
- Novartis is a Repeat Offender for Fraudulent Drug Marketing | 8/29/2018
- Peripheral Artery Disease Plagues Tasigna Patients | 8/27/2018
- Patients Could Have Benefited From Gleevec's Generic Alternative | 8/21/2018
- Novartis/Tasigna Lawsuit May Seek Punitive Damages | 8/17/2018
- Tasigna Atherosclerosis Trial Set to Proceed | 8/14/2018
- Medical Websites Ignore Tasigna's Risks | 8/10/2018
- Novartis haste in rushing Tasigna to market has cost patients their lives | 8/8/2018
- Tasigna's Side Effects Require Special Attention From Prospective Patients | 8/6/2018
- Novartis Whistleblower Receives $12 Million For His Efforts | 7/31/2018
- Tasigna Atherosclerosis Hidden From Americans | 7/30/2018
- Gleevec Was a Cancer-Curing Miracle Drug | 7/26/2018
- Tasigna Stroke Victim's Trial to Proceed in Florida | 7/24/2018
- Novartis Employee Blows Whistle on Tasigna Fraud and Others | 7/20/2018
- Tasigna Side Effects Are Worse Than Cancer | 7/18/2018
- Tasigna Cancer Medication Carries More Risks Than Others | 7/11/2018
- Specialty Pharmacists Bribed to Prescribe Tasigna | 7/6/2018
- Novartis Billion-Dollar Fine for Fraudulent Marketing Tactics | 7/2/2018
- Tasigna Black Box Warning Addendum | 6/29/2018
- Tasigna Replaced Gleevec and Patients Suffered | 6/25/2018
- Specialty Pharmacists Selling Tasigna Compromised Ethical Standards | 6/20/2018
- US Department of Justice Fines Novartis One Billion Dollars | 6/13/2018
- Tasigna Sudden Death Warning | 6/11/2018
- Tasigna Cancer Treatment Poses Scary Risks | 6/7/2018
- Tasigna Atherosclerosis Warning Never Made it to the US | 5/25/2018
- Novartis Tasigna Anti-Cancer Drug Has Side Effects That Include Sudden Death | 5/22/2018
- Tasigna Replaced Gleevec Under Fraudulent Circumstance | 5/18/2018
- Novartis Held Accountable For Concealing Tasigna Atherosclerosis Risk | 5/15/2018
- Tasigna Chemotherapy Carries a Sudden Death Warning | 5/10/2018
- Novartis Warns That Tasigna Can Cause Atherosclerosis | 5/6/2018
- Tasigna Poses Atherosclerosis Amputations Risk | 5/3/2018
- Tasigna Rushed to Market to Replace Gleevec | 12/29/2017
- Whistleblower Saves American Taxpayers Millions | 12/22/2017
- Gleevec-the Novartis AG Wonder Drug | 12/20/2017
- Tasigna Warnings | 12/18/2017
- Tasignas Black Box Warning Links The Drug To Atherosclerosis | 12/15/2017
- Novartis Fails To Warn The U.S. Medical Community About The Side Effects of Tasigna | 12/11/2017
- Tasigna Replaces Gleevec as the Novartis AGs Signature Anti-Cancer Chemotherapy Drug | 12/6/2017
- The Unmistakable Signs of Peripheral Artery Disease | 12/1/2017
- Whistleblower Causes Public Alert to Tasigna Side Effects | 11/27/2017
- The Estate of a California Man is Suing Novartis | 11/20/2017
- Ex-Novartis Salesmanager Blows The Whistle On Illegal Drug Marketing | 11/13/2017
- U.S. Cancer Patients Receive Tasigna Atherosclerosis Warning | 11/6/2017
- Novartis Marketed Tasigna to Replace Gleevec | 11/3/2017
- Leukemia Patients May Suffer From Heart Disease as Well | 10/30/2017
- Novartis' Potentially Misleading Drug Marketing Campaign | 10/23/2017
- Health Canada Issued a Tasigna Health Warning In 2013 | 10/16/2017
- Lawsuits Allege Novartis Was Aware of The Side Effects of Tasigna Yet Failed to Warn The American Public | 10/9/2017
- Tasigna Chemotherapy Atherosclerosis-related Side Effects | 10/2/2017
- The Onder Law Firm Seeks to Hold Novartis Accountable for the Suffering Tasigna Has Caused Families | 9/29/2017
- Novartis Fails to Warn About Tasigna Atherosclerosis | 9/22/2017
- Side Effects of Tasigna Cancer Drug Include Atherosclerosis and Peripheral Artery Disease | 9/15/2017
- Novartis Put Profits Ahead of Patients | 9/7/2017
- Novartis Failed to Warn the American Medical Community of the Side Effects of Tasigna | 9/1/2017
- Atherosclerosis Linked to Tasigna Anti Cancer Drug | 8/18/2017
- You Can Sue Novartis If You Have Developed Atherosclerosis-Related Conditions After Taking Tasigna | 8/11/2017
- Who Can Be Considered A Tasigna Victim | 8/4/2017
- Novartis AG makers of Tasigna Failed to Warn Public of the Dangerous Side Effects | 7/14/2017
- Tasigna Anti Cancer Drug Lawsuit | 7/7/2017
- Tasigna Drug Warning for Peripheral Arterial Disease | 6/30/2017
- Tasigna Cancer Treatment Drug Lawsuit | 6/26/2017
- Novartis International AG Lawsuits | 6/23/2017
- Lawsuits Against Novartis International AG Makers of Tasigna | 6/21/2017
- Tasigna Peripheral Artery Disease Warning | 6/19/2017
- Tasigna Lawsuits Against Drug Makers Novartis | 6/16/2017
- Atherosclerosis of the Aorta Linked to Tasigna Anti-Cancer Drug | 6/12/2017
- Makers of Tasigna Leukemia Drug Lawsuit | 6/9/2017
- Tasigna a Cancer Drug Treatment | 6/5/2017
- Tasigna Peripheral Arterial Disease | 6/1/2017
Lawyers for Tasigna Atherosclerosis Lawsuits
Attorneys handling Tasigna lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Tasigna lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Tasigna lawsuit. The product liability litigators handling Roundup claims at the Onder Law Firm have a strong track record of success in representing families harmed by dangerous drugs and consumer products.